Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company dedicated to advancing the development of novel neuropsychiatric drugs in areas of unmet patient needs. The company has a proven strategy to advance clinically validated mechanisms that were previously hindered by limitations overcome by the company's proprietary Glyph™ technology platform. All candidate therapies in Seaport Therapeutics' first-in-class and best-in-class drug pipeline are based on the Glyph platform, which is uniquely designed to achieve oral bioavailability, bypass first-pass metabolism, and reduce hepatotoxicity and other side effects.